2 material Form 8-K filings that 2 companies we cover made with the SEC in March 2013, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
The Board of Trustees of H&Q Life Sciences Investors authorized a renewal of the Fund's share repurchase program, as announced in a March 22, 2013 press release. The renewed program lets the Fund buy back up to 12% of its outstanding common shares in the open market through July 10, 2014, a one-year extension of the current program's July 10, 2013 end date. The Board says the program aims to narrow the discount between the share price and net asset value per share.
Renewed program allows open-market purchases of up to 12% of outstanding common shares.
Renewed program runs for one year, ending July 10, 2014; the current program ends July 10, 2013.
Tekla Capital Management LLC, the Fund's investment adviser, will decide the amount and timing of repurchases.
The filing states there is no assurance of purchases at any specific discount level, amount or date.
H&Q Healthcare Investors, a closed-end fund listed on the NYSE as HQH, said its Board of Trustees renewed its share repurchase program. The renewal lets the fund buy back up to 12% of its outstanding common shares in the open market for a one-year period ending July 10, 2014, replacing the current program that ends July 10, 2013. The Board said the goal is to reduce the discount between the share price and net asset value per share, though the filing gives no assurance of any specific repurchase amount or discount level.
Renewed program allows open-market purchases of up to 12% of outstanding common shares
Current program runs through July 10, 2013; renewal extends the period to July 10, 2014
Timing and amount of repurchases are at the discretion of Tekla Capital Management LLC, the fund's investment adviser
The filing states there is no assurance that repurchases will narrow the discount or raise the share price
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.